Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

NCT05205330 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Metastatic Colorectal Cancer
Solid Tumor
Metastatic Microsatellite-stable Colorectal Cancer
Mismatch Repair Protein Proficient
Metastatic GI Cancers
Gastric Cancer

Interventions

DRUG: CR6086
BIOLOGICAL: AGEN2034

Sponsor

Rottapharm Biotech

Collaborators

[object Object]